Catalent Pharma Solutions has signed an agreement with PATH, an international nonprofit organization supporting global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI). Catalent Biologics will use its GPEx cell line technology, coupled with an ambr workstation, which mimics the characteristics of classical bioreactors at micro scale, to develop, optimize the process for expression, and manufacture antibodies under cGMP conditions at its Madison, WI facili...